It is well documented that niclosamide can inhibit different molecular targets (STAT3, mTOR, Wnt/b-catenin, S100A4, SQSTM1/p62, NF-kB, Notch, TMEM16) [9,10] which are all dysregulated and pathogenic in ALS [[11], [12], [13]], suggesting its application to interfere with these altered mechanisms to improve multiple aspects of the pathology. The gene discussed is SQSTM1; the disease is amyotrophic lateral sclerosis.